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RESULTS

RESULTS

• A total of 986 subjects met usage criteria for octreotide infusion
• 83 subjects were excluded due to the following criteria leaving 903
subjects for the final analysis

Potential Reasons for Inappropriate Duration

•

To characterize the appropriate use of octreotide infusions for
gastroesophageal bleeding at a community hospital system to
pursue guideline-driven standardization of care

BACKGROUND
• Octreotide is a somatostatin analogue used in the management of
acute variceal hemorrhage by selectively constricting splanchnic
blood vessels1
• When used for variceal hemorrhage, octreotide is recommended to
be given as an initial 50 mcg IV bolus followed by a continuous
infusion of 50 mcg/hr for a duration of 2-5 days2,3
• Use beyond 2-5 days is not recommended, as studies have not
demonstrated any benefit beyond this time frame4,5
• Anecdotal reports describe broader application of octreotide
infusions within this community hospital system for the use of
gastroesophageal bleeding that may not align with treatment
guidelines
• This medication use evaluation was conducted to evaluate
prescribing habits to help achieve guideline-driven standardization of
octreotide infusion use

Exclusion Criteria
Subjects

Adult patients > 18 years of age

< 18 years of age

Received at least one octreotide
infusion for gastroesophageal
bleeding

Received octreotide for indication other than
gastroesophageal bleeding (i.e. hepatorenal syndrome,
carcinoid crisis, etc)
Received subcutaneous octreotide
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• Data was also collected to evaluate potential reasoning for octreotide
to be initiated or continued outside of guideline recommendations,
such as decreased hemoglobin values, increased need of
vasopressors, and continued need for blood transfusions
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Note: subjects could meet multiple criteria
Potential Reasons for Inappropriate Initiation
Reason

Required
vasopressors

Hgb minimum value within
24 hours of initiation

Received blood
transfusion

Home medication with
increased bleeding risk

Subjects (n=179)

42

102

92

24

Length of Inappropriate Continuation
6-7 days

10

6

5

Hgb min value >5 days
after initiation

Blood transfusion

Home medication with
increased bleeding risk

1. Lexi-Drugs/Octreotide, Lexicomp app. UpToDate Inc. Accessed September 15, 2022.
2. Octreotide acetate [package insert]. East Hanover, NJ: Novartis; 2002.
3. Garcia-Tsao, Guadalupe et al. ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal
Varices and Variceal Hemorrhage in Cirrhosis. American Journal of Gastroenterology. 2007;102:2086-2102.
4. Corley, DA et al. Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology. 2001
Mar;120(4):946-54.
5. Rengesamy S et al. Comparison of 2 days versus 5 days of octreotide infusion along with endoscopic therapy in
preventing early rebleed from esophageal varices: a randomized clinical study. European Journal of Gastroenterology
and Hepatology. 2015 Apr;27(4):386-92.

32
4

11-12 days

5

>13 days

5
0

14

15

REFERENCES

Note: subjects could fit into multiple categories

8-10 days

20

• In the 20% of subjects where octreotide initiation was deemed
inappropriate, providers likely chose to utilize octreotide due to
evidence of generalized uncontrolled gastroesophageal bleeding which
is not supported by clinical guidelines or primary literature, as it
should only be initiated for suspected or confirmed variceal bleeding
• Inappropriate use of octreotide can lead to potential avoidable
adverse effects such as sinus bradycardia and biliary tract disease
• Based on the WAC pricing for octreotide for this health system,
inappropriate initiation of octreotide led to an unnecessary
additional cost of ~$28,000
• For subjects continued on octreotide for >5 days, it seems providers
were employing any available option for subjects with ongoing
bleeding or in a shock state requiring vasopressors
• Despite intentions to treat patients with any medication that may
be beneficial to control GI bleeding, primary literature demonstrates
no added benefit with use of >5 days
• Inappropriate continuation of therapy in this evaluation led to an
additional cost for the health system of ~$7,900
• Our health system and others must continue to be diligent in our use
of this medication potentially through specific embedded ordering
parameters for guideline-driven standardization of care to ensure
outcomes with this costly therapy
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Ordering physician is gastroenterology
Must not exceed 5 consecutive days
specialist
Confirmed diagnosis of gastroesophageal
variceal hemorrhage through
esophagogastroduodenoscopy (EGD)
Suspected variceal hemorrhage based on past
medical history (PMH) of cirrhosis, alcoholism,
liver disease, or previous variceal hemorrhage
Suspected variceal hemorrhage based on
performance of a transjugular intrahepatic
portosystemic shunt (TIPS) procedure
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• In accordance with treatment guidelines, appropriateness was
assessed based on the following criteria specific for initiation and
duration of octreotide use:
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DISCUSSION & CONCLUSIONS

80%
N=724

Received > 2 bolus doses of octreotide
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Note: subjects could fit into multiple categories

450

Exclusion Criteria

Initiation (must meet >1 criteria)
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Non-GI bleed

20%
N=179

Number of subjects (n=724)
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SubQ dose received

Initiation of octreotide

METHODS
• Retrospective chart review of all adult patients who received an
octreotide infusion at two hospitals within a community health
system from July 2019 to July 2022
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